Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19

doi:10.1038/s41401-021-00851-w

	Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19
	Wu, Can-rong 1; Yin, Wan-chao 1; Jiang, Yi 1; Xu, H. Eric1,2
	2022-01
发表期刊	ACTA PHARMACOLOGICA SINICA (IF:6.9[JCR-2023],7.6[5-Year])
ISSN	1671-4083
EISSN	1745-7254
发表状态	已发表
DOI	10.1038/s41401-021-00851-w
摘要	Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has brought an unprecedented public health crisis and persistently threatens to humanity. With tireless efforts from scientists around the world, understanding of the biology of coronavirus has been greatly enhanced over the past 2 years. Structural biology has demonstrated its powerful impact on uncovering structures and functions for the vast majority of SARS-CoV-2 proteins and guided the development of drugs and vaccines against COVID-19. In this review, we summarize current progress in the structural biology of SARS-CoV-2 and discuss important biological issues that remain to be addressed. We present the examples of structure-based design of Pfizer's novel anti-SARS-CoV-2 drug PF-07321332 (Paxlovid), Merck's nucleotide inhibitor molnupiravir (Lagevrio), and VV116, an oral drug candidate for COVID-19. These examples highlight the importance of structure in drug discovery to combat COVID-19. We also discussed the recent variants of Omicron and its implication in immunity escape from existing vaccines and antibody therapies.
关键词	COVID-19 SARS-CoV-2 structural biology omicron drug design vaccine development
URL	查看原文
收录类别	SCI ; SCIE
语种	英语
资助项目	Ministry of Science and Technology (China)[2018YFA0507002] ; Shanghai Municipal Science and Technology Major Project[2019SHZDZX02] ; CAS Strategic Priority Research Program[XDB08020303] ; National Natural Science Foundation of China[31770796] ; Youth Innovation Promotion Association of CAS[2021278]
WOS研究方向	Chemistry ; Pharmacology & Pharmacy
WOS类目	Chemistry, Multidisciplinary ; Pharmacology & Pharmacy
WOS记录号	WOS:000744808000001
出版者	NATURE PUBL GROUP
引用统计	被引频次：69[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	https://kms.shanghaitech.edu.cn/handle/2MSLDSTB/153541
专题	生命科学与技术学院_特聘教授组_徐华强组
通讯作者	Wu, Can-rong; Xu, H. Eric
作者单位	1.Chinese Acad Sci, Shanghai Inst Mat Med, CAS Key Lab Receptor Res, Shanghai 201203, Peoples R China 2.ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai 201210, Peoples R China
通讯作者单位	生命科学与技术学院
推荐引用方式 GB/T 7714	Wu, Can-rong,Yin, Wan-chao,Jiang, Yi,et al. Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19[J]. ACTA PHARMACOLOGICA SINICA,2022.
APA	Wu, Can-rong,Yin, Wan-chao,Jiang, Yi,&Xu, H. Eric.(2022).Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19.ACTA PHARMACOLOGICA SINICA.
MLA	Wu, Can-rong,et al."Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19".ACTA PHARMACOLOGICA SINICA (2022).